Johnson & Johnson’s Vaccine Is Less Effective Than Rivals. Here’s Why It Could Still Win Big

Johnson & Johnson (NYSE: JNJ) is about to cross the coronavirus vaccine race finish line. But cheers may not be as loud as they were for rivals Pfizer (NYSE: PFE) and Moderna (NASDAQ: MRNA). That’s because the big pharmaceutical company reported efficacy that lagged that of tRead MoreMarketsMarkets Feed

¡Haz clic para votar esta entrada!
(Votos: 0 Promedio: 0)

Deja un comentario